Tonix Pharmaceuticals Publishes Peer-Reviewed Publication In MSphere Journal Highlighting Tolerability Of Its Single-Dose Mpox And Smallpox Vaccine Candidate TNX-801, In Immune-Compromised Animals
Tonix Pharmaceuticals Publishes Peer-Reviewed Publication In MSphere Journal Highlighting Tolerability Of Its Single-Dose Mpox And Smallpox Vaccine Candidate TNX-801, In Immune-Compromised Animals
The World Health Organization (WHO) declared the spread of new Clade Ib Mpox a public health emergency of international concern (PHEIC): Second Mpox-related WHO PHEIC declaration in two years
世界衛生組織(WHO)將新克萊德Ib Mpox的傳播宣佈爲國際關注的公共衛生緊急事件(PHEIC):這是兩年來第二次與Mpox相關的WHO PHEIC聲明
Clade Ib Mpox cases detected in 16 African countries and outside of Africa, in Sweden, Thailand, Singapore, India, Germany and England
在16個非洲國家以及瑞典、泰國、新加坡、印度、德國和英國發現了克萊德Ib Mpox病例
Single-dose mpox vaccines with durable protection may be required to address global health emergency
可能需要單劑量的mpox疫苗以提供持久的保護,來應對全球健康緊急事件
TNX-801 was shown to be more than 10- to 1,000-fold more attenuated (or less virulent) compared to the older vaccinia smallpox vaccines: Tolerability of TNX‐801 vaccination in immune-compromised animal models supports clinical development
與舊的水痘疫苗相比,TNX-801的減毒超過了10到1,000倍(或致病性更低):TNX-801在免疫受損動物模型中的耐受性支持了其臨床開發
譯文內容由第三人軟體翻譯。